NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER (NSQ NSCLC)

Clinical trials for NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER (NSQ NSCLC) explained in plain language.

Never miss a new study

Get alerted when new NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER (NSQ NSCLC) trials appear

Sign up with your email to follow new studies for NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER (NSQ NSCLC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Terminated 1

New drug combo tested for Tough-to-Treat lung cancer

Disease control Terminated

This study tested whether adding a new targeted drug called tusamitamab ravtansine to standard immunotherapy and chemotherapy could better control advanced lung cancer. It involved 57 adults with a specific type of non-small cell lung cancer that had spread and tested positive fo…

Matched conditions: NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER (NSQ NSCLC)

Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control

Last updated Mar 30, 2026 14:31 UTC

NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER (NSQ NSCLC)

Get alerted when new NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER (NSQ NSCLC) trials appear

New drug combo tested for Tough-to-Treat lung cancer